THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Clinical trials for THERAPY-RELATED MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for THERAPY-RELATED MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New chemo cocktail aims to keep leukemia from coming back after transplant
Disease control OngoingThis study tests whether giving two chemotherapy drugs (clofarabine and melphalan) before a donor stem cell transplant can help prevent leukemia from returning in patients whose cancer is in remission. The approach aims to kill any remaining cancer cells and stop the immune syste…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 11:40 UTC
-
New stem cell therapy aims to tame transplant complications in blood cancer patients
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special stem cell transplant designed to reduce serious side effects like graft-versus-host disease. The trial compares Orca-T to standard stem cell transplants in 187…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 26, 2026 11:28 UTC
-
New drug combo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to standard therapy. The goal is to find the best dose and see how well th…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:27 UTC
-
New combo shows promise for Treatment-Linked blood cancer
Disease control OngoingThis study tests whether combining venetoclax and azacitidine can help people with a type of blood cancer called therapy-related myelodysplastic syndrome (t-MDS), which develops after prior cancer treatments. About 33 adults with intermediate to very high risk t-MDS will receive …
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 22, 2026 14:04 UTC